China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the submission of a market filing for its seasonal influenza vaccine in Brazil. This move marks a strategic expansion for the company as it seeks to broaden the reach of its vaccine offerings.
Product Details and Advantages
The product in question is a quadrivalent split inactivated vaccine designed for the prevention of influenza. It contains hemagglutinin from four influenza virus strains, comprising two A and two B strains. This quadrivalent composition enhances the vaccine’s effectiveness by providing coverage against a wider range of potential seasonal influenza B strains, offering an advantage over trivalent vaccines. The vaccine received marketing approval in China in January 2022 for use in individuals aged three years and older.
Brazilian Market Potential and Full-Year Sales Cycle
The approval of Clover Biopharmaceuticals’ influenza vaccine in Brazil would complement the company’s existing market in the Northern Hemisphere, enabling a full-year sales cycle. This is crucial for maximizing the product’s market potential and ensuring a continuous supply of the vaccine to meet global demand throughout the year.-Fineline Info & Tech
